CTVA Stock Analysis — Corteva
Sector: Agriculture
AI Verdict
Corteva trades at 21.7x next year's earnings while analysts expect EPS to more than double, making it cheap for the growth on offer if its IP and regulatory moat keeps competitors at bay.
Competitive Moat
Corteva specializes in proprietary crop protection chemicals and genetically engineered seeds, giving it a defensible moat through intellectual property and regulatory barriers that make it hard for new entrants to compete. Its deep R&D pipeline and global distribution network reinforce its position with farmers and agribusinesses.
Summary
Corteva's stock is deeply oversold with an RSI of 10.4, while analysts expect a dramatic 109.3% jump in earnings next year.
Where It Stands
Corteva has delivered a modest 2.9% revenue growth but trades at 21.7x forward earnings—below the 20x industrials median—while its RSI of 10.4 signals extreme oversold territory.
Key Metrics
- RSI: 10.4 — Oversold
- Trailing P/E: 45.4x
- Forward P/E: 21.7x
- PEG Ratio: 0.42
- Earnings Growth: +1.1%
- Revenue Growth: +0.0%
- Dividend Yield: 0.01%
- 52-Week High: $85.63
- 52-Week Low: $60.53
Analyst Consensus
22 Buy · 8 Hold · 0 Sell (30 analysts)
Bull Case
With forward EPS growth forecast at 109.3% and a forward P/E of 21.7x, the stock is cheap for the growth on offer, especially if its IP-driven moat holds.
Bear Case
If the P/E reverts toward the sector median or RSI normalizes, even a 20% pullback would erase much of the anticipated upside.
Catalyst to Watch
Watch for the next earnings report to confirm whether the triple-digit EPS growth materializes, as a miss could trigger further volatility.